Real-world cohort links frontline bevacizumab to longer survival in advanced ovarian cancer

In a retrospective real-world cohort of 128 patients with advanced ovarian cancer, frontline bevacizumab use was associated with better overall and progression-free survival in the overall population, while ovarian clear cell carcinoma independently predicted poorer outcomes than high-grade serous ovarian cancer. The study, summarized in an early-access BMC Cancer article, included 42 patients with clear cell carcinoma and 86 with high-grade serous carcinoma treated at China Medical University Hospital between January 2017 and December 2022. Because it was an observational, single-institution study, the results show associations rather than establishing that bevacizumab caused the survival differences.

Patients with clear cell carcinoma were younger than those with high-grade serous carcinoma, with reported ages of 51 versus 58 years, and they had lower CA-125 levels. They also received frontline PARP inhibitors less frequently: 4.8% compared with 24% among patients with high-grade serous disease, a difference with a p value of 0.007. The objective response rate was numerically higher among bevacizumab recipients than among patients who did not receive the drug, at 90% versus 78%, but this comparison did not meet the conventional statistical threshold (p = 0.078).

Bevacizumab use was also associated with a different recurrence pattern. The abstract reported disseminated peritoneal recurrence in 31% of bevacizumab recipients versus 49% without bevacizumab, while pelvic or focal recurrence occurred in 15% and 2.2%, respectively; the overall comparison between recurrence patterns had a p value of 0.025. Kaplan–Meier analyses found significantly better overall survival (p = 0.0012) and progression-free survival (p = 0.01) with bevacizumab across the full cohort. The overall-survival association was particularly pronounced in the high-grade serous subgroup (p = 0.0061).

In multivariable analysis, clear cell histology independently predicted worse overall survival, with a hazard ratio of 3.03 (95% confidence interval, 1.71–5.34; p < 0.001), and worse progression-free survival, with a hazard ratio of 1.81 (95% CI, 1.10–3.00; p = 0.02). Frontline bevacizumab was independently associated with longer overall survival, with a hazard ratio of 0.52 (95% CI, 0.30–0.90; p = 0.019). The survival association in the clear cell subgroup did not reach statistical significance, although its direction was consistent with that in high-grade serous carcinoma, and no significant interaction by histology was detected (p = 0.505). The authors noted that the retrospective design and limited subgroup sizes require validation in prospective studies; the supplied evidence is an abstract from an early-access version subject to further edits, not a full assessment of the article.

Subject of Research: Associations between frontline bevacizumab, survival, and recurrence patterns in advanced ovarian cancer by histology

Article Title: Frontline bevacizumab in ovarian clear cell versus high-grade serous ovarian cancer: survival outcomes and recurrence patterns in a real-world cohort

Article References: Gao, Y.-T., Chang, C. Y.-Y., Chang, W.-C., Hung, Y.-C., Lin, W.-C., Sung, Y.-W., & Yeh, L.-S. (2026). Frontline bevacizumab in ovarian clear cell versus high-grade serous ovarian cancer: survival outcomes and recurrence patterns in a real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17030-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17030-x

Keywords: ovarian cancer, bevacizumab, clear cell carcinoma, high-grade serous carcinoma, overall survival, progression-free survival, recurrence patterns, retrospective cohort, observational study, Frontline, ovarian, clear